

Fig. 1A




Fig. 1B




Figure 2




Figure 3





Figure 4

Figure 5











Figure 6









Fig. 7A






Fig. 7B










Figure 8

Compound name	Structure	IDO inhibition @ 250 $\mu$ M	TDO inhibition @ 250 $\mu$ M	Ratio IDO:TDO inhibition
1-DL-Methyl-Tryptophan		25.32%	4.74%	5.34
9-Vinylcarbazole		22.94%	19.33%	1.19
Acemetacin		30.25%	N.D.	N.D.
5-Bromo-DL-tryptophan		31.49%	18.05%	1.74
Acemetacin		32.55%	12.44%	2.62
5-Bromoindoxyl diacetate		59.72%	N.D.	N.D.

### Thiohydantoin (TH) derivatives of indoleamine




phenyl-TH-DL-trp (PTH-trp)		56.95%	17.83%	3.19
propenyl-TH-DL-trp (propTH-trp)		62.72%	25.17%	2.49
methyl-TH-DL-trp (MTH-trp)		68.40%	27.05%	2.53

Figure 9




Figure 10

Figure 11

